Biocept Inc (BIOC):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Biocept Inc (BIOC) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C6588
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:87
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. Biocept offers related instrumentation, OncoCEE technology, and analytical capabilities for rare event detection and genetic characterization. The company’s OncoCEE platform modifies rare cell capture and analyses methods. It serves cancer diagnostic assays to oncologists and other physicians; hospitals, and cancer centers. Biocept also provides clinical trial and research services to pharmaceutical and biopharmaceutical companies; and clinical research organizations. Biocept is headquartered in San Diego, California, the US.

Biocept Inc (BIOC) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biocept Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Biocept Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Biocept Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Biocept Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Biocept Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Biocept Inc, Medical Equipment, Deal Details 12
Partnerships 12
Biocept Enters into Marketing Agreement with Miraca Life Sciences 12
Biocept Enters into Agreement with University of Texas Southwestern Medical Center 13
Addario Lung Cancer Medical Institute and Biocept Enter into Partnership 14
Biocept Enters into Agreement with OHSU Knight Cancer Institute 15
Biocept Enters into Agreement with Catalyst Pharma 16
Biocept Enters into Agreement with Teneovita Medical Innovations 17
Biocept Forms Partnership with MedStar Georgetown University Hospital 18
Biocept to Form Partnership with Quest Diagnostics Mexico 19
Biocept Enters into Agreement 20
Biocept Enters into Distribution Agreement with Progenetics 21
Biocept Enters into Co-Development Agreement with Baylor College of Medicine 22
Biocept and Insight Genetics Enter into Agreement 23
Biocept Enters into Partnership with Life Technologies 24
Equity Offering 25
Biocept Raise USD11.6 Million in Rights Offering of Units 25
Biocept Prices Public Offering of Shares for USD2.5 Million 27
Biocept Raises USD14.8 Million in Public Offering of Shares and Warrants 29
Biocept Prices Public Offering of Shares for USD3.3 Million 31
Biocept Prices USD3.3 Million in Public Offering of Shares 33
Biocept Plans to Raise Funds through Private Placement of Shares 34
Biocept to Raise USD2.2 Million in Private Placement of Shares and Warrants 35
Biocept Prices Private Placement of Shares and Warrants for USD9.3 Million 36
Biocept Raises USD10 Million in Public Offering of Shares and Warrants 37
Biocept Prices Public Offering of Shares and Warrants for USD5 Million 38
Biocept to Raise USD15 Million in Public Offering of Shares 39
Biocept Raises USD10 Million in Public Offering of Shares and Warrants 40
Biocept Completes IPO For US$19 Million 42
Biocept Raises USD2 Million in Private Placement of Series A Preferred Stock 43
Biocept Inc – Key Competitors 44
Biocept Inc – Key Employees 45
Biocept Inc – Locations And Subsidiaries 46
Head Office 46
Recent Developments 47
Financial Announcements 47
Aug 14, 2018: Biocept reports second quarter 2018 financial results 47
May 15, 2018: Biocept Announces First Quarter 2018 Financial Results 50
Mar 28, 2018: Biocept Reports 2017 Fourth Quarter and Full Year Financial Results 52
Nov 09, 2017: Biocept Reports Third Quarter 2017 Financial Results 55
Aug 10, 2017: Biocept Reports Second Quarter 2017 Financial Results 58
May 11, 2017: Biocept Reports First Quarter 2017 Financial Results 61
Mar 07, 2017: Biocept Reports Fourth Quarter and Full Year 2016 Financial Results 63
Corporate Communications 65
Sep 10, 2018: Biocept names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer 65
Oct 11, 2017: Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept’s Clinical Advisory Board 66
Feb 15, 2017: Biocept Appoints Michael Terry Senior Vice President Commercial Operations 67
Government and Public Interest 68
Jan 30, 2018: Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer 68
Product News 69
Sep 24, 2018: Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy 69
Aug 02, 2018: Biocept awarded patent in Canada for its target selector CTC platform 70
Jul 31, 2018: European patent granted for Biocept’s target selector oncogene mutation enrichment and detection platform 71
Jun 11, 2018: VWR and Biocept Announce the Launch of CEE-Sure Blood Collection Tubes for cfDNA and CTCs 72
Mar 20, 2018: Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio’s 11th Biomarker Summit 73
Mar 15, 2018: Biocept’s Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting 74
Feb 05, 2018: Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform 75
Jan 04, 2018: Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources 76
Dec 05, 2017: First U.S. Patent Issued for Biocept’s Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform 77
Other Significant Developments 78
Jul 23, 2018: Biocept and UC San Diego Moores Cancer Center announce collaboration to study feasibility of liquid biopsy to predict disease recurrence in solid tumors and response to therapy 78
Jul 17, 2018: Alliance Global to market Biocept liquid biopsy tests 79
Mar 28, 2018: Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration 80
Dec 18, 2017: Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota 81
Oct 18, 2017: Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals 82
Aug 14, 2017: Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR 83
Aug 07, 2017: Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform 84
Jun 21, 2017: Biocept and MediNcrease Health Plans Announce Provider Agreement Expanding Access to Liquid Biopsy Testing 85
Jan 10, 2017: Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87

List of Tables
Biocept Inc, Medical Equipment, Key Facts, 2017 2
Biocept Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Biocept Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Biocept Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Biocept Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Biocept Inc, Deals By Market, 2012 to YTD 2018 9
Biocept Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Biocept Enters into Marketing Agreement with Miraca Life Sciences 12
Biocept Enters into Agreement with University of Texas Southwestern Medical Center 13
Addario Lung Cancer Medical Institute and Biocept Enter into Partnership 14
Biocept Enters into Agreement with OHSU Knight Cancer Institute 15
Biocept Enters into Agreement with Catalyst Pharma 16
Biocept Enters into Agreement with Teneovita Medical Innovations 17
Biocept Forms Partnership with MedStar Georgetown University Hospital 18
Biocept to Form Partnership with Quest Diagnostics Mexico 19
Biocept Enters into Agreement 20
Biocept Enters into Distribution Agreement with Progenetics 21
Biocept Enters into Co-Development Agreement with Baylor College of Medicine 22
Biocept and Insight Genetics Enter into Agreement 23
Biocept Enters into Partnership with Life Technologies 24
Biocept Raise USD11.6 Million in Rights Offering of Units 25
Biocept Prices Public Offering of Shares for USD2.5 Million 27
Biocept Raises USD14.8 Million in Public Offering of Shares and Warrants 29
Biocept Prices Public Offering of Shares for USD3.3 Million 31
Biocept Prices USD3.3 Million in Public Offering of Shares 33
Biocept Plans to Raise Funds through Private Placement of Shares 34
Biocept to Raise USD2.2 Million in Private Placement of Shares and Warrants 35
Biocept Prices Private Placement of Shares and Warrants for USD9.3 Million 36
Biocept Raises USD10 Million in Public Offering of Shares and Warrants 37
Biocept Prices Public Offering of Shares and Warrants for USD5 Million 38
Biocept to Raise USD15 Million in Public Offering of Shares 39
Biocept Raises USD10 Million in Public Offering of Shares and Warrants 40
Biocept Completes IPO For US$19 Million 42
Biocept Raises USD2 Million in Private Placement of Series A Preferred Stock 43
Biocept Inc, Key Competitors 44
Biocept Inc, Key Employees 45

List of Figures
Biocept Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Biocept Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Biocept Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Biocept Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Biocept Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Biocept Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Biocept Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Biocept Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Biocept Inc (BIOC):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Maxim Power Corp.:発電所・企業SWOT分析
    Maxim Power Corp. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Medshape Inc:医療機器:M&Aディール及び事業提携情報
    Summary Medshape Inc (MedShape), formerly MedShape Solutions Inc, is a medical device company that develops and manufactures orthopedic devices for the orthopedic healthcare markets. The company provides products such as dynanail ankle arthrodesis nail, eclipse soft tissue anchor, exoshape teno soft …
  • Entreprise Tunisienne d’Activites Petrolieres:企業の戦略的SWOT分析
    Entreprise Tunisienne d'Activites Petrolieres - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Albireo Pharma Inc (ALBO):製薬・医療:M&Aディール及び事業提携情報
    Summary Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe med …
  • Bangkok Bank Public Co Ltd:戦略・SWOT・企業財務分析
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Varian Medical Systems, Inc.:企業の戦略・SWOT・財務情報
    Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Amgen Inc (AMGN):企業の財務・戦略的SWOT分析
    Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Genmedica Therapeutics SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Genmedica Therapeutics SL (Genmedica) is a clinical-stage biopharmaceutical company that researches, discovers and develops orally available NCEs for the treatment of diabetes. The company’s expertise spans provides development of specific, dual-action, small molecule inhibitors that targets …
  • LuLu Group International:企業の戦略・SWOT・財務情報
    LuLu Group International - Strategy, SWOT and Corporate Finance Report Summary LuLu Group International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Metinvest BV:企業の戦略・SWOT・財務分析
    Metinvest BV - Strategy, SWOT and Corporate Finance Report Summary Metinvest BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Federal-Mogul Holdings LLC:企業の戦略的SWOT分析
    Federal-Mogul Holdings LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Grupo Grana y Montero SAA (GRAMONC1):企業の財務・戦略的SWOT分析
    Grupo Grana y Montero SAA (GRAMONC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • McKinsey & Company, Inc.:企業の戦略・SWOT・財務情報
    McKinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary McKinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Societe Generale Private Banking:企業の戦略・SWOT・財務分析
    Societe Generale Private Banking - Strategy, SWOT and Corporate Finance Report Summary Societe Generale Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Hansen Technologies Ltd (HSN):企業の財務・戦略的SWOT分析
    Summary Hansen Technologies Ltd (Hansen Technologies) is a technology company that offers customer care, billing, and meter data management software solutions. The company provides outsourcing services such as facilities management, support center, consulting, host management, business continuity, i …
  • Qatar National Bank (QNBK):企業の財務・戦略的SWOT分析
    Qatar National Bank (QNBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Energy XXI Gulf Coast Inc (EXXIQ):企業の財務・戦略的SWOT分析
    Summary Energy XXI Gulf Coast Inc (Energy XXI) is an oil and gas company that explores and develops oil and natural gas assets. The company’s projects include West Delta, South Timbalier, South Pass, Main Pass, and Ship Shoal. Its West Delta property is located 28 miles offshore of Grand Isle, Louis …
  • Johnson Matthey PLC:企業の戦略・SWOT・財務情報
    Johnson Matthey PLC - Strategy, SWOT and Corporate Finance Report Summary Johnson Matthey PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Green Cross Cell Corp (031390):製薬・医療:M&Aディール及び事業提携情報
    Summary Green Cross Cell Corp (Green Cross Cell), a subsidiary of Green Cross Corp, is a provider of immunotherapeutics for the treatment of cancer. The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient. It offers cryopreservation of co …
  • Ratchaburi Electricity Generating Holding Public Co Ltd:企業の発電所・SWOT分析2018
    Ratchaburi Electricity Generating Holding Public Co Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆